Clinical Trials
40 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
ACCOMPLISH
National Cancer Center, Korea
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Pan-MSI-ACSE
UNICANCER
INTERVAL
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Sun Yat-sen University
PEMBR-01
Maria Sklodowska-Curie National Research Institute of Oncology
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
CaboACC
Wuerzburg University Hospital
PESETA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
West China Hospital
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
SIRAC
University of Wuerzburg
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Burzynski Research Institute
CabACC
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
ABACUS
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Spanish Oncology Genito-Urinary Group
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Dartmouth-Hitchcock Medical Center
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
SWOG Cancer Research Network
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
Rigshospitalet, Denmark
PAXO
University of Turin, Italy
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
National Institutes of Health Clinical Center (CC)
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
Adherex Technologies, Inc.